Enhancing the value of the ASCO value framework

Research output: Research - peer-reviewArticle

Standard

Enhancing the value of the ASCO value framework. / Morton, Alec; Bach, Peter B.; Briggs, Andrew.

In: Medical Decision Making Policy & Practice, 29.05.2018.

Research output: Research - peer-reviewArticle

Harvard

Morton, A, Bach, PB & Briggs, A 2018, 'Enhancing the value of the ASCO value framework' Medical Decision Making Policy & Practice. DOI: 10.1177/2381468318776223

APA

Morton, A., Bach, P. B., & Briggs, A. (2018). Enhancing the value of the ASCO value framework. Medical Decision Making Policy & Practice. DOI: 10.1177/2381468318776223

Vancouver

Morton A, Bach PB, Briggs A. Enhancing the value of the ASCO value framework. Medical Decision Making Policy & Practice. 2018 May 29. Available from, DOI: 10.1177/2381468318776223

Author

Morton, Alec ; Bach, Peter B. ; Briggs, Andrew. / Enhancing the value of the ASCO value framework. In: Medical Decision Making Policy & Practice. 2018

BibTeX - Download

@article{3a7d40f10a3942f393c320b25301eff4,
title = "Enhancing the value of the ASCO value framework",
abstract = "The last few years have seen the development of several “value frameworks” for assessing the relative merits and prices of cancer drugs, including ASCO’s own value framework (Schnipper et al, 2016). These frameworks can have many different aims and audiences (Neumann and Cohen, 2015; Mandelblatt et al, 2017). For example they may be designed to support social decisions about value, as in the case of DrugAbacus . ASCO’s framework is designed to support individual clinical decisions through comparative assessment of treatment alternatives, contemplated as part of the dialogue between patient and physician. In this paper we inquire as to whether the ASCO framework can be considered as a valid system for measuring patient value, and thus for supporting decisions. We contrast it with some tools which have been developed by those within and affiliated with the Medical Decision Making community, with a view to making constructive suggestions for the ongoing development of the framework.",
keywords = "value frameworks, cancer drugs, ASCO value framework, patient value",
author = "Alec Morton and Bach, {Peter B.} and Andrew Briggs",
year = "2018",
month = "5",
doi = "10.1177/2381468318776223",
journal = "Medical Decision Making Policy & Practice",
issn = "2381-4683",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Enhancing the value of the ASCO value framework

AU - Morton,Alec

AU - Bach,Peter B.

AU - Briggs,Andrew

PY - 2018/5/29

Y1 - 2018/5/29

N2 - The last few years have seen the development of several “value frameworks” for assessing the relative merits and prices of cancer drugs, including ASCO’s own value framework (Schnipper et al, 2016). These frameworks can have many different aims and audiences (Neumann and Cohen, 2015; Mandelblatt et al, 2017). For example they may be designed to support social decisions about value, as in the case of DrugAbacus . ASCO’s framework is designed to support individual clinical decisions through comparative assessment of treatment alternatives, contemplated as part of the dialogue between patient and physician. In this paper we inquire as to whether the ASCO framework can be considered as a valid system for measuring patient value, and thus for supporting decisions. We contrast it with some tools which have been developed by those within and affiliated with the Medical Decision Making community, with a view to making constructive suggestions for the ongoing development of the framework.

AB - The last few years have seen the development of several “value frameworks” for assessing the relative merits and prices of cancer drugs, including ASCO’s own value framework (Schnipper et al, 2016). These frameworks can have many different aims and audiences (Neumann and Cohen, 2015; Mandelblatt et al, 2017). For example they may be designed to support social decisions about value, as in the case of DrugAbacus . ASCO’s framework is designed to support individual clinical decisions through comparative assessment of treatment alternatives, contemplated as part of the dialogue between patient and physician. In this paper we inquire as to whether the ASCO framework can be considered as a valid system for measuring patient value, and thus for supporting decisions. We contrast it with some tools which have been developed by those within and affiliated with the Medical Decision Making community, with a view to making constructive suggestions for the ongoing development of the framework.

KW - value frameworks

KW - cancer drugs

KW - ASCO value framework

KW - patient value

UR - http://journals.sagepub.com/home/mpp

U2 - 10.1177/2381468318776223

DO - 10.1177/2381468318776223

M3 - Article

JO - Medical Decision Making Policy & Practice

T2 - Medical Decision Making Policy & Practice

JF - Medical Decision Making Policy & Practice

SN - 2381-4683

ER -

View graph of relations